Multidisciplinary and multifaceted outpatient management of patients with osteoarthritis: protocol for a randomised, controlled trial by Moe, Rikke Helene et al.
STUDY PROTOCOL Open Access
Multidisciplinary and multifaceted outpatient
management of patients with osteoarthritis:
protocol for a randomised, controlled trial
Rikke Helene Moe
*, Till Uhlig, Ingvild Kjeken, Kåre Birger Hagen, Tore Kristian Kvien, Margreth Grotle
Abstract
Background: Osteoarthritis (OA) is a prevalent joint disorder with a need for efficient and evidence-based
management strategies.
Objectives: The primary purpose of this study is to compare the effects of a multidisciplinary outpatient clinic,
including a brief group-based educational programme, with a traditional individual outpatient clinic for patients
with hip, knee, hand or generalized OA. A secondary purpose is to investigate the effects of a telephone
follow-up call.
Methods: This is a pragmatic randomised single-blind controlled study with a total of 400 patients with hip, knee,
hand or generalized OA between 40 and 80 years referred to an outpatient rheumatology hospital clinic. The
randomisation is stratified according to the diagnostic subgroups. The experimental group is exposed to a
multidisciplinary and multifaceted intervention, including a 3.5 hour group-based patient education programme
about OA in addition to individual consultations with members of a multidisciplinary team. The control
intervention is based on regular care with an individual outpatient consultation with a rheumatologist (treatment
as usual). Primary outcomes are patient satisfaction measured at 4 months and cost-effectiveness measured at
12 months. Secondary outcomes are pain and global disease activity measured on a numeric rating scales (NRS),
generic and disease specific functioning and disability using Short Form-36 (SF-36) health survey, the Western
Ontario and McMaster Universities Osteoarthritis Index 3 (WOMAC), the Australian/Canadian Osteoarthritis Hand
Index (AUSCAN), and a patient-generated measure of disability (Patient-Specific Functional scale, PSFS). Global
perceived effect of change in health status during the study period is also reported. At 4-month follow-up, patients
in both groups will be randomly allocated to a 10-minute telephone call or no follow-up ("treatment as usual”).
After additional 8 months (12-month follow-up) the four groups will be compared in a secondary analysis with
regard to health outcomes and health care costs.
Discussion: This trial will provide results on how multidisciplinary and multifaceted management of patients with
OA affects health outcomes and health care costs.
Trial registration: Current Controlled Trials ISRCTN25778426
Background
Osteoarthritis (OA) is the most prevalent joint disorder
and is associated with pain, functional disability and
impaired quality of life [1]. The degenerative disease
process of synovial joints leads to radiographic signs and
the clinical symptoms like pain, stiffness and reduced
joint motion. OA is strongly associated with aging, has
most commonly an onset after the age of 50 years, and
is ranked as the fourth most common condition in older
women and the eight most common in older men [2-4].
OA poses significant burdens in terms of reduced gen-
eral health [5], work disability [6], and large societal costs
which may be comparable to rheumatoid arthritis and
other inflammatory diseases [7-9]. With an increasing
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any medium, provided the original work is properly cited.proportion of older people in the population, OA consti-
tutes a growing public health problem. Effective and
evidence-based preventive and treatment strategies for
OA are important as they may reduce both the individual
burden of OA, and the economic burden to the society.
Recommendations for management of OA focus on a
combination of pharmacological and non-pharmacological
treatments [3,10,11]. Most of the non-pharmacological
treatments have been studied in patients with hip and
knee OA with a special focus on exercise, physical activity,
patient education and weight control [2]. Reduced pain
and improved function has been documented in patients
with knee OA, and exercises and information are consid-
ered as important non-pharmacological interventions for
this patient group.
Non-pharmacological management of hand OA and
generalized OA has been investigated in only a few stu-
dies [12]. One recent systematic review concerning treat-
ment of hand OA included 31 studies, most of them on
the effect of pharmacological treatment [12]. Even
though a few of the treatment strategies did show effect
in terms of reduced pain and improved function, metho-
dological weaknesses made direct recommendations on
treatments for hand OA impossible. Various patient edu-
cation programmes have been used for treating chronic
health conditions, but no consensus has been reached on
how patient education shouldb ea p p l i e d ;e i t h e ru s i n ga
disease specific or generic approach, group-based or indi-
vidual education, and either given by health professionals
or lay tutors [13,14].
Standard treatment for OA in specialist care is an
individual consultation with a rheumatologist, some-
times followed by referral to one or several other health
professionals. However, many patients with OA experi-
ence this provision of health services as fragmented.
Due to an increasing demand for a more coordinated
approach, a pilot multidisciplinary OA outpatient clinic
was established at Diakonhjemmet Hospital, Oslo, Nor-
way, in 2003. The multidisciplinary team included rheu-
matologists, nurses, health secretaries, occupational
therapists, physical therapists, pharmacists, orthopaedic
surgeons and a dietician. Over a two year period,
approximately 300 patients with OA were referred to
the OA clinic by their general practitioners or specia-
lists. Of these 300, 73 patients were followed for 1 year
[15]. Most (78%) of these patients were women (mean
age 61 years (range 24-92)). More than 60% reported to
have pain in their knees and/or hands, while 40% had
pain primarily localized to the hip. Approximately one
fourth of the patients used NSAIDS and/or other types
of analgesics. At the one year follow-up, 95% of the
patients were very satisfied with the team care received,
and pain and functioning was moderately improved
[15]. This first evaluation with an open longitudinal
design without a control group warranted the need for a
more systematically and thorough evaluation of the
effect and cost-benefits of this multidisciplinary, coordi-
nated outpatient OA clinic.
The number of referrals to the clinic increased in the
pilot period. To meet patients’ need for information, a
brief group-based educational programme was devel-
oped. Thus, in the updated multidisciplinary OA clinic,
starting from 2005, patients first receive a 3.5 hours
group education. After a lunch brake, they have indivi-
dual consultations with a rheumatologist and thereafter,
dependent on identified needs, also have encounters
with other health professionals.
Few other studies have evaluated the effect of group-
based educational programmes for OA in combination
with a pragmatic individual approach, especially in a set-
ting of a randomised clinical trial (RCT) [13].
The purposes of this study are 1) to compare the effect
of a multidisciplinary outpatient clinic, including a brief
group-based educational programme, with a regular care
individual outpatient clinic for patients with hip, knee,
hand and/or generalized OA, and 2) to compare the effect
of a telephone follow-up call with follow-up “as usual” for
patients with hip, knee, hand and/or generalized OA.
Hypotheses
1) Patients with hip, knee, hand and/or generalized OA
who receive a multidisciplinary and multifaceted inter-
vention will be more satisfied with the health service at
4-month follow up compared to patients who receive
individual consultation(s) in a regular care individual
outpatient clinic.
2) The multidisciplinary and multifaceted outpatient
clinic will reduce the use of health services and thus,
this intervention will be more cost-effective at 12-month
follow up than the traditional individual outpatient
clinic.
3) Patients who receive a telephone call after 4
months will at 12-month follow-up report more satisfac-
tion with the health service than those within the same
group allocation who do not receive any telephone
follow-up.
4) At 4- and 12-month follow-up, changes in the sec-
ondary outcomes VAS pain, global disease activity, gen-
eric and disease specific functioning and disability
(measured by SF-36, WOMAC and AUSCAN) will not
be different between patients who are managed in a
multidisciplinary outpatient clinic and patients who
receive regular care in a traditional individual outpatient
clinic.
Methods
Patients are randomised into the two interventions
within three strata: patients with primary hand, hip or
Moe et al. BMC Musculoskeletal Disorders 2010, 11:253
http://www.biomedcentral.com/1471-2474/11/253
Page 2 of 7knee problems. A project coordinator includes patients
and coordinates the patient-reported data collection
with questionnaires. Health professionals who are taking
part in the two interventions are not involved in the
data collection. Blinding of providers and patients is not
possible in this type of study, but the outcome assessors
as well as those who perform the follow up telephone
call are blinded. All patients involved in the project have
signed an informed consent and have been informed
according to the Helsinki declaration. The data inspec-
torate and the regional ethical committee (REK)
reviewed and approved the project (REK ref 156-06073
1.2006.598); the ISRCTN trial number is 25778426.
Study sample and setting
A total of 400 participants referred to an outpatient hospi-
tal rheumatology clinic with a diagnosis of hip, knee, hand
and/or generalized OA, will be recruited for the study.
Subjects
To be eligible for inclusion, participants must be between
40 and 80 years and have a clinical diagnosis of hip, knee,
hand and/or generalized OA confirmed by a specialist.
The eligibility criteria are described in Table 1.
Primary intervention
The experimental intervention is a multidisciplinary and
multifaceted intervention, in which the referred patients
first receive a 3.5 hour group-based educational pro-
gramme, and thereafter individual consultations with a
rheumatologist and other members of the multidisciplin-
ary team, dependent on identified needs. The multidisci-
plinary team consists of rheumatologists, an orthopaedic
surgeon, nurses, health secretaries, physiotherapists,
occupational therapists, a pharmacist and a dietician.
The group-based educational programme contains
four main themes identified through qualitative inter-
views with patient advocates. The themes are: a) What
is OA? b) Activity possibilities or limitations, what can
we do ourselves? c) Treatment options and d) How to
live with OA.
The control intervention is regular care in an individual
outpatient clinic. The patients are referred to and exam-
ined by a rheumatologist. According to usual procedures
they are referred to other specialists or health profes-
sionals such as orthopaedic surgeons, physiotherapists,
occupational therapists etc. dependent on identified
needs. The access to health care providers is in principle
similar to the access in the experimental group, but
encounters occur according to referral.
Secondary intervention
Patients in both the primary groups are randomised to
either a short ‘telephone call’ or ‘no telephone call’ after
they have completed the 4-month follow-up assessment.
Patients who receive ‘no telephone call’ are treated as
usual, which imply that they can contact the outpatient
clinic if they have additional questions or comments.
Patients who receive the ‘telephone call’ are asked the fol-
lowing three questions: “how are you doing?”, “did you
receive the help you needed for your OA when you were
at the hospital?”,a n d“do you want to add any further
information concerning your health status and the treat-
ment given"?
Recruitment procedure
All referrals from general practitioners to the outpatient
clinic with focus on OA are screened for eligibility accord-
ing to the inclusion and exclusion criteria. A research
coordinator contacts patients who are potentially eligible
for the study by telephone, inform them about the study
and ask whether they want to participate. In the same tele-
phone contact, a screening tool for classification of OA is
used in the cases in which an OA diagnosis was evident
based on information in the referral letter [16]. If the OA
diagnosis cannot be clinically confirmed during the exami-
nation by the rheumatologist during the first appointment,
the participant will be excluded. Written consent accord-
ing to the declarations of Helsinki is obtained before
enrolment to the study. In addition, they are sent the first
q u e s t i o n n a i r eb ym a i lt ob ef i l l e di nb e f o r et h ef i r s t
appointment at the outpatient clinic.
Group allocation
All patients are randomly allocated to one of two groups,
experimental or control group. This randomisation is
performed after completion of the baseline question-
naires. To ensure equal-sized treatment groups, random
permuted blocks of 4-8 participants are used [17]. The
stratified random allocation schedule is computer gener-
ated by a statistician who is not otherwise involved in
recruitment, assessment or treatment of participants.
The randomisation sequence is carried out in sequen-
tially numbered, opaque, sealed envelopes.
Table 1 Eligibility criteria







40-80 years Inability to read and understand
Norwegian
Recent trauma in the extremities, other
known or relevant co-morbidities such
as rheumatoid arthritis and cancer
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The participants are at the 4-month follow-up asked to
complete a mailed questionnaire, and return it by mail.
After completion of the questionnaire, participants are
randomly allocated to either a brief ‘telephone call’ of
approximately 10 minutes or follow-up “as usual”, which
means that the patients may contact the clinic if they
need to.
The final follow-up is a mailed questionnaire at
12 months, which is mailed back to the project group
after completion. In addition to these two mailed
follow-up questionnaires, the participants complete a
monthly diary regarding use of health care.
The administration of questionnaires is carried out by
a person not otherwise involved in the treatment of par-
ticipants (research coordinator AF). The telephone calls
are carried out by two researchers (IK, ES) who are
blinded to group allocation. Figure 1 provides an over-
view of the design and follow-up assessments.
Outcome measures
Table 2 provides an overview of the various question-
naires used at data collection at baseline, after 4 and
12 months.
Primary outcomes
The primary outcome measure is patient satisfaction
with the health service, which will be evaluated on a
11 point numeric rating scale (NRS) from 0 = not satis-
fied to 10 = very satisfied [18]. The co-primary outcome
is cost-effectiveness, which will be based on changes in
utility-scores based on EQ-5D in the denominator [19]
and direct and indirect costs related to OA in the
numerator. The costs will be assessed by recording the
use of health care by patient self-report. All patients will
receive a diary and all consultations and costs related to
OA care during the follow-up will be recorded in this
diary. Indirect costs related to the disease, like sick
leave, lost working days and the use of social security
will also be included in this cost-effectiveness analysis.
Secondary outcomes
Secondary outcomes are pain and global disease activity,
generic and disease specific functioning and disability
using the component summary scales in the SF-36
health survey, WOMAC, AUSCAN, a patient-generated
measure of disability (PSFS), and global perceived effect
of change in health status during the study period.
Pain is measured on a NRS (range 0-10) with the
anchor words ‘no pain at all’ and ‘unbearable pain’. Glo-
bal disease activity is measured on a NRS (0-10) with
the anchor words ‘no symptoms’ and ‘extremely severe’,
answering the question: “All symptoms taken into
account, what do you think about your condition the
last week?”
Health related quality of life is measured by the generic
questionnaire SF-36 [20]. The SF-36 Health Survey is a
widely used generic instrument that comprises eight
health scales that contribute to two higher order health
scales, the Physical Component Summary (PCS) and Men-
tal Component Summary (MCS) summary scores which
give a mean (SD) of 50 based on normative data from the
general population (Ware, 1995). The SF-36 is often used
to assess health related quality of life in the general popu-
lation and in different diseases. The English version has
been translated to and validated in Norwegian [21].
Disease specific functioning in daily life is assessed by
the WOMAC [22] for patients with hip or knee OA.
This instrument is responsive and valid for measuring
pain (5 items), stiffness (2 items) and physical function
(17 items). The Likert scale version of the scale is used
with response options none, mild, moderate, severe,
extreme.
For patients with hand OA disease specific health pro-
blems are self-reported by the AUSCAN, which com-
prises 15 items relating to hand stiffness (one item),
pain (five items) and problems with performance of
activities (nine items). This study used the five-point
descriptive scale version of the AUSCAN with response
options none, mild, moderate, severe, extreme [23].
Through the use of the PSFS, all patients will also be
asked to describe the three most important activity lim-
itations caused by their OA and score each of these on
a 0-10 point scale according to the ability to perform
these activities [24]. Patients will be interviewed regard-
ing their activity limitations during the telephone inter-
view at baseline before randomisation.
The global perceived effect of change in health status
during the study period will be assessed on a 5-point
scale ranging from much better through unchanged to
much worse.
Self-efficacy will be evaluated using the Arthritis Self
Efficacy Scale (ASES) for pain and functioning [25].
Baseline questionnaire
All patients are asked to fill in a questionnaire at inclu-
sion, containing information on socio-demographics
(age, gender, height, weight, marital status, work situa-
tion, emotional distress and physical activity), earlier
and current pharmacological and non-pharmacological
treatment for their OA and co-morbidities. They are
also asked to complete standardised instruments for
measurement of pain; functioning and health related
quality of life.
Additional therapies and co-interventions are also
registered. Patients who withdraw from the study will be
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tions in both groups will be registered by the health
professionals responsible for the intervention. Register-
ing co-interventions will be part of the diary.
Data analysis
Power calculations
As no satisfactory data on patient satisfaction and cost-
effectiveness were available, power calculations were
based on the secondary outcome pain with data from
the pilot study and previous research on OA from our
group [26-28]. In this RCT we compare two indepen-
dent equally sized groups. We assume comparable varia-
tion in both groups, set alpha to 5%, beta to 80%, and
assume a smallest clinical important difference between
the groups of 0.20 based on an estimated difference for
pain measured by WOMAC/AUSCAN. The standar-
dized difference (0.20)/SD (0.70)) will be 0.25. According
to the Altman nomogram, approximately 200 patients
will be needed in each of the two treatment groups.
Statistical analyses
Primary data analysis will be performed in a blinded
manner, by conducting the effect analyses without
knowing which intervention each of the two groups
received. The treatment groups will be examined for
baseline comparability. Both parametric and nonpara-
metric statistical analyses will be used, dependent on how
the variance is distributed. Effect of the interventions will
be analyzed according to intention-to treat principles.
Further, exploratory analyses will be performed to study
the treatment effect within the three subgroups hip, knee
and hand OA.
Discussion
To our knowledge, this will be one of the first RCT’s
that will examine how a multidisciplinary approach
affects treatment outcomes for patients with OA. Pri-
mary outcome will be patient satisfaction with health
service assessed at 4 months, while, cost-effectiveness
will be the co-primary outcome assessed at 12 months,
and various aspects of health status are the secondary
outcomes at both time-points.
A rheumatologist and a project coordinator examine all
referrals to the multidisciplinary OA clinic at Diakonhjem-
met Hospital. Patients aged 18-80 years are recruited to
the study by a screening-form for OA based on clinical
Figure 1 Design and assessments in the study.
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eligible for the study receive oral and written information
about the methods and aims of the study and are informed
that participation is voluntary and can be terminated at
any time without stating a reason and without any impact
on their care. Informed consent will be obtained from all
patients. They receive questionnaires by mail before the
clinical examinations and if they have problems answering
questions, a project assistant at the first encounter provide
assistance. A smaller self-reported questionnaire on func-
tion, pain and health status will be mailed to the patients
for the 4- and 12-month assessments.
All health professionals in the multidisciplinary team
are represented among the staff at the Department of
Rheumatology and a research secretary will be responsi-
ble for performance of practical aspects and organisation.
Time schedule
Data collection is ongoing, and will be completed within
2011 which will be followed by a one-year period of
data analyses and manuscript preparation.
The project will, by means of a randomised controlled
trial, contribute to new knowledge on the effect of
patient education for patients with OA. The project will
also contribute with cost-effectiveness analyses compar-
ing the two different methods of outpatient care.
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